No negative symptoms in healthy volunteers after single doses of amisulpride, aripiprazole, and haloperidol: A double-blind placebo-controlled trial

International Clinical Psychopharmacology

Volumn 27, Issue 2, 2012, Pages 114-120

  Park, Chul Hyun ^a   Park, Tae Won ^a   Yang, Jong Chul ^a   Lee, Keon Hak ^c   Huang, Guang Biao ^a   Tong, Zhao ^a   Park, Myung Sook ^b   Chung, Young Chul ^a  

^a Chonbuk National University Medical School   (South Korea)

^b Chonbuk National University   (South Korea)

^c In san Medical Foundation   (South Korea)

Author keywords

Amisulpride; Aripiprazole; Negative symptom; Neuroleptic induced deficit syndrome

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; HALOPERIDOL; PLACEBO; RISPERIDONE;

ABDOMINAL DISCOMFORT; ADULT; AKATHISIA; ALOGIA; ANXIETY DISORDER; ARTICLE; BLUNTED AFFECT; BLURRED VISION; COGNITIVE DEFECT; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG FEVER; DRUG INDUCED HEADACHE; DYSPHORIA; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; MALE; NEGATIVE SYNDROME; NEUROLEPTIC INDUCED DEFICIT SYNDROME SCALE; NORMAL HUMAN; PARALLEL DESIGN; PRIORITY JOURNAL; PSYCHOLOGICAL RATING SCALE; RANDOMIZED CONTROLLED TRIAL; SALIVATION; SCALE FOR THE ASSESSMENT OF NEGATIVE SYMPTOM; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; SUBJECTIVE DEFICIT SYNDROME SCALE; TACHYCARDIA;

ADULT; ANTIPSYCHOTIC AGENTS; DIZZINESS; DOUBLE-BLIND METHOD; FEMALE; HALOPERIDOL; HUMANS; HYPNOTICS AND SEDATIVES; MALE; MILD COGNITIVE IMPAIRMENT; NEUROTOXICITY SYNDROMES; PIPERAZINES; PSYCHIATRIC STATUS RATING SCALES; QUINOLONES; RISPERIDONE; SEVERITY OF ILLNESS INDEX; SULPIRIDE; TIME FACTORS; YOUNG ADULT;

EID: 84862777599     PISSN: 02681315     EISSN: 14735857     Source Type: Journal    
DOI: 10.1097/YIC.0b013e3283502773     Document Type: Article

References (47)

1. American Psychiatric Association (1997). Practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry 154:1-63.
2. Andreasen NC (1984). Modified Scale for the Assessment of Negative Symptoms (SANS). Iowa City: University of Iowa.
3. Artaloytia JF, Arango C, Lahti A, Sanz J, Pascual A, Cubero P, et al. (2006). Negative signs and symptoms secondary to antipsychotics: a double-blind, randomized trial of a single dose of placebo, haloperidol, and risperidone in healthy volunteers. Am J Psychiatry 163:488-493. (Pubitemid 44469392)
4. Awad AG, Hogan TP (1994). Subjective response to neuroleptics and quality of life: implications for treatment outcome. Acta Psychiatr Scand 89:27-32. (Pubitemid 24147816)
5. Barnes TRE (1989). A rating scale for drug-induced akathisia. Br J Psychiatry 154:672-676.
6. Beuzen JN, Taylor N,Wesnes K,Wood A (1999). A comparison of the effects of olanzapine, haloperidol and placebo on cognitive and psychomotor functions in healthy elderly volunteers. J Psychopharmacol 13:152-158. (Pubitemid 29276826)
7. Bond A, Lader M (1974). The use of analogue scales in rating subjective feelings. Br J Med Psychol 47:211-218.
8. 3 dopamine occupancy sufficient for atypical antipsychotic effect? An in vivo quantitative [123I]epidepride SPET study of amisulpride-treated patients. Am J Psychiatry 160:1413-1420. (Pubitemid 41070915)
9. Burris KD, Molski TF, Xu C, Ryan E, Tottori K, Kikuchi T, et al. (2002). Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 302:381-389. (Pubitemid 34680462)
10. 2 receptor occupancy induced by atypical antipsychotics in stabilized schizophrenic patients. J Psychopharmacol 22:882-894.
11. Correll CU (2007). Acute and long-term adverse effects of antipsychotics. CNS Spectrums 12 (Suppl 21):10-14.
12. 2 receptor occupancy in patients with recentonset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study. Am J Psychiatry 160:303-309. (Pubitemid 41110456)
13. DeLeon A, Patel NC, Crismon ML (2004). Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clin Ther 26:649-666. (Pubitemid 38736956)
14. First M, Spitzer RL, Gibbon M,William JB (1997). Structured clinical interview for DSM-IV Axis I disorders, research version, non-patient edition. New York: Biometrics Research, New York State Psychiatric Institute.
15. Foussias G, Mann S, Zakzanis KK, Van Reekum R, Remington G (2009). Motivational deficits as the central link to functioning in schizophrenia: a pilot study. Schizophr Res 115:333-337.
16. Froemming JS, Francis Lam YW, Jann MW, Davis CM (1989). Pharmacokinetics of haloperidol. Clin Pharmacokinet 17:396-423. (Pubitemid 20020153)
17. Gründer G, Carlsson A, Wong DF (2003). Mechanism of new antipsychotic medications. Arc Gen Psychiatry 60:974-977.
18. Han OS, Hong JP (2000). Structured clinical interview for DSM-IV Axis I disorders, research version. Seoul: Hana Medical Publisher.
19. 2 receptor occupancy by the secondgeneration antipsychotic drug risperidone in humans: a positron emission tomography study. Int J Neuropsychopharmacol 12:667-675.
20. Jaeger J, Bitter I, Czobor P, Volavka J (1990). The measurement of subjective experience in schizophrenia: the Subjective Deficit Syndrome Scale. Compr Psychiatry 31:216-226. (Pubitemid 20169114)
21. Kane JM, Leucht S, Carpenter D, Docherty JP (2003). Optimizing pharmacologic treatment of psychotic disorders. J Clin Psychiatry 64 (Suppl 12):5-94.
22. Karow A, Czekalla J, Dittmann RW, Schacht A,Wagner T, Lambert M, et al. (2007). Association of subjective well-being, symptoms, and side effects with compliance after 12 months of treatment in schizophrenia. J Clin Psychiatry 68:75-80. (Pubitemid 46220127)
23. King DJ (1990). The effect of neuroleptics on cognitive and psychomotor function. Br J Psychiatry 157:799-811.
24. Lader MH (1993). Neuroleptic-induced deficit syndrome. J Clin Psychiatry 54:493-494.
25. D-amphetamine in humans. Neuropsychopharmacology 30:2103-2114. (Pubitemid 43093509)
26. 2 receptors: a PET study in schizophrenia. Am J Psychiatry 164:630-637. (Pubitemid 46650195)
27. 2 receptors in patients treated with a dopamine partial agonist and full antagonist antipsychotics. Int J Neuropsychopharmacol 12:715-721.
28. 18F-Fallypride. Neuropsychopharmacology 25:476-488. (Pubitemid 32830952)
29. Naber D, Moritz S, Lambert M, Rajonk F, Holzbach R, Mass R, et al. (2001). Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs. Schizophr Res 50:79-88. (Pubitemid 32510889)
30. Naber D, Karow A, Lambert M (2005). Subjective well-being under the neuroleptic treatment and its relevance for compliance. Acta Psychiat Scand 427:29-34. (Pubitemid 40780197)
31. Ramaekers JG, Louwerens JW, Muntjewerff ND, Milius H, De Bie A, Rosenzweig P, et al. (1999). Psychomotor, cognitive, extrapyramidal, and affective functions of healthy volunteers during treatment with an atypical (amisulpride) and a classic (haloperidol) antipsychotic. J Clin Psychopharmacol 19: 209-221. (Pubitemid 29233015)
32. Robinson DG,Woerner MG, Napolitano B, Patel RC, Sevy SM, Gunduz-Bruce H, et al. (2006). Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes. Am J Psychiatry 163:2096-2102. (Pubitemid 46114229)
33. Schooler N, Rabinowitz J, Davidson M, Emsley R, Harvey PD, Kopala L, et al. (2005). Early Psychosis Global Working Group: risperidone and haloperidol in first episode psychosis: a long-term randomized trial. Am J Psychiatry 162:947-953.
34. 2 atypical antipsychotics. Am J Psychiatry 162:1984-1985. (Pubitemid 41428639)
35. Simpson GM, Angus JWS (1970). A rating scale for extrapyramidal side effects. Acta Psychiat Scand (Suppl 212):11-19.
36. Sparshatt A, Taylor D, Patel MX, Kapur S (2009). Amisulpride-dose, plasma concentration, occupancy and response: implications for therapeutic drug monitoring. Acta Psychiat Scand 120:416-428.
37. Tessier C, Nuss P, Staneva G, Wolf C (2008). Modification of membrane heterogeneity by antipsychotic drugs: an X-ray diffraction comparative study. J Colloid Interface Sci 320:469-475.
38. Van Putten T (1974). Why do schizophrenic patients refuse to take their drugs? Arc Gen Psychiatry 31:67-72.
39. Van Putten T, May PRA, Marder SR (1981). Subjective response to antipsychotic drugs. Arch Gen Psychiatry 38:187-190. (Pubitemid 11142771)
40. Verhoeff NP, Kapur S, Hussey D, Lee M, Christensen B, Psych C, et al. (2001). A simple method to measure baseline occupancy of neostriatal dopamine D2 receptors by dopamine in vivo in healthy subjects. Neuropsychopharmacology 25:213-223. (Pubitemid 32566343)
41. Verhoeff NP, Christensen BK, Hussey D, Lee M, Christensen B, Psych C, et al. (2003). Effects of catecholamine depletion on D2 receptor binding, mood, and attentiveness in humans: a replication study. Pharmacol Biochem Behav 74:425-432. (Pubitemid 35449529)
42. Voruganti L, Slomka P, Zabel P, Costa G, So A, Matter A, et al. (2001). Subjective effects of AMPT-induced dopamine depletion in schizophrenia: correlation between dysphoric responses and striatal D(2) binding ratios on SPECT imaging. Neuropsychopharmacology 25:642-650. (Pubitemid 32995946)
43. Wezenberg E, Sabbe BGC, Hulstijn W, Ruigt GSF, Verkes RJ (2007). The role of sedation tests in identifying sedative drug effects in healthy volunteers and their power to dissociate sedative-related impairments from memory dysfunctions. J Psychopharmacol 21:579-587. (Pubitemid 47472724)
44. Williams SA, Wesnes K, Oliver SD, Rapeport WG (1996). Absence of effect of sertraline on time-based sensitization of cognitive impairment with haloperidol. J Clin Psychiatry 1 (57 Suppl):7-11. (Pubitemid 26143028)
45. Woods SW (2003). Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry 64:663-667. (Pubitemid 36750143)
46. 3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride. Neuropsychopharmacology 27: 248-259. (Pubitemid 34692591)
47. Zevin S, Benowitz NL (1999). Drug interactions with tobacco smoking. An update. Clin Pharmacokinet 36:425-438.